New York, US – January 22, 2019 – Creative Biolabs, a leading provider engaged in one-stop solution CAR development, recently releases scFv generation services from hybridoma cell lines, phage display library, antibody sequence, to align with specific needs of scientific and industrial customers.
As the most critical initial step, the generation of specific scFv and the optimization of its superior affinity lay down the most basic foundation of an effective and specific CAR-T therapy. Through three mature and delicate technologies for scFv construction, Creative Biolabs is able to greatly accelerate the research progress with much lower unpredictable risk.
Hybridoma Cell Lines
Seasoned scientists in Creative Biolabs can generate scFv from Hybridoma Cell Lines by immunizing mice with the antigen, and then removing the spleen to get splenocytes (B cells). After the splenocytes and myeloma cells fusion step, hybridoma cell lines will be established for producing specific monoclonal antibodies. The Fv fragment can be converted from full monoclonal antibody into a scFv, which can target a specific tumor antigen customers interested in. Finally, this scFv is cloned together with other CAR components into a lentivirus vector for the future steps.
In this technology, an immunized phage display scFv library is established to screen out the antigen of interest by firstly designing the suitable primers for cloning the antibody genes from B lymphocytes of different species, and integrating the antibody genes into a phage display vector. The recombinant phagemid population will then be transformed into Escherichia coli in which phage-displayed scFv is generated depending on the helper phage. In the last critical step, this scFv phage display library is screened with the specific antigen from customers or the self-made recombinant antigen, which can achieve a capacity of over 1×1010 clones.
The scFv generation from existed antibody sequence is the fastest approach for getting an engineered antibody fragment, in which the gene sequences of two variable regions are synthesized in vitro and fused with a short peptide linker gene. Subsequently, this long fragment is inserted into a vector and expressed in E. coli or a mammalian cell line. Meanwhile, further services for the purification of this recombinant antibody are available for the next step research.
With professional service and various technology platforms, experts in Creative Biolabs are confident to offer the best screening and optimization for superior affinity. In addition, the customs sequences of scFv are also welcomed for further optimization, cDNA synthesis, and subsequent service. If you are interested in any scFv services or CAR-T therapy, please visit https://www.creative-biolabs.com/car-t/ for more comprehensive information.
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States